Header graphic for print
LimeGreenIP News

Stella Wong

Posts by Stella Wong

3D printing: Opportunities & risks for the pharma industry

3D printing is transforming certain industries – so why hasn’t it been widely adopted in the pharma sector? There are likely to be a number of barriers to entry for 3D printing in this field, including identifying how to make it economically viable. Whilst a number of the key patents relating to 3D printing have

A problem in 3D – Opportunities and IP risks for businesses

“The UK Intellectual Property Office is wary, designers are worried, and the EU is embracing the tech.” In this Intellectual Property Magazine July/August article, Stella Wong examines the awkward relationship between 3D printing and IP. Issues discussed include: Opportunities in the consumer and life sciences industries (such as customised toys, or better tolerated medicines) Infringement challenges

3D Printing: Are you 3DP Ready?

3D printing has already been around for decades and has disrupted certain industries, such as hearing aids. One likely impact is an increase in IP infringement, with Gartner predicting that this could reach $100 billion a year by 2018. Now that a number of key patents have expired, 3D printers are becoming cheaper and offer

LSIPR Video interview – The 3D printed pill: A reality with opportunities & risks

You would be wrong to think that the 3D printed pill is “the next big thing” – it already exists and the FDA has already authorised such a pill. In an interview with Life Sciences IP Review, Stella Wong outlines why pharma and medical device companies should be looking at the opportunities and risk mitigation around this disruptive